Core Viewpoint - Purcell & Lefkowitz LLP is investigating Pulse Biosciences, Inc. to determine if the company's directors breached their fiduciary duties related to recent corporate actions [1]. Group 1 - The investigation is on behalf of Pulse Biosciences' shareholders [1]. - The law firm specializes in representing shareholders affected by securities fraud and breaches of fiduciary duty [3]. - Shareholders can obtain additional information regarding their rights and options at no cost [2].

Financial Data and Key Metrics Changes - In Q1 2024, total GAAP costs and expenses increased by $1 million to $10.6 million compared to $9.6 million in the prior year period, primarily due to an increase in non-cash stock-based compensation expense, which rose to $1.8 million from $0.9 million [23][47] - Cash and cash equivalents totaled $34.9 million as of March 31, 2024, down from $44.4 million as of December 31, 2023, with cash used in Q1 2024 amounting to $9.5 million compared to $7.2 million in the same period last year [24] Business Line Data and Key Metrics Changes - The company has treated 30 patients for soft tissue ablation for thyroid disease using the CellFX nsPFA system, with no serious adverse events reported [16][17] - For cardiac indications, 24 out of 30 patients have been successfully treated with the CellFX nsPFA 360-degree Cardiac Catheter, with the remaining six expected to be treated within the next 45 days [19] Market Data and Key Metrics Changes - The company received FDA 510(k) clearance for its non-cardiac CellFX nsPFA percutaneous system in March 2024, which is used for soft tissue ablation across various procedures [40] - The company plans to have a strong presence at the upcoming Heart Rhythm Society meeting, featuring six poster presentations and a live case presentation [43][62] Company Strategy and Development Direction - The company is committed to advancing its proprietary CellFX nsPFA energy delivery system and plans to conduct multiple clinical trials across different indications [15] - A rights offering of up to $60 million is planned to secure necessary capital for advancing its devices towards market entrance [44][45] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth and the potential of its technology to improve treatment outcomes, emphasizing the importance of building strong clinical support for physicians [15][27] - Ongoing discussions with the FDA regarding the clinical pathway for the CellFX nsPFA Surgical Clamp indicate a collaborative approach to regulatory requirements [30][60] Other Important Information - The company has submitted an application to the Ethics Committee in the Netherlands for a first-in-human feasibility study with the CellFX nsPFA Surgical Clamp, expecting a response soon [42] - The rights offering is expected to provide funding for the company's growth plans into the first quarter of 2026 [45] Q&A Session Summary Question: How is the pilot launch going in the U.S. with the percutaneous electrode now that it's approved? - The interest level has been high among physicians at major institutions, and the company expects the CellFX percutaneous system to be used in several prominent hospitals by the end of the year [26][27] Question: Can you provide details on the FDA dialogue and the pivotal program? - The company has had productive discussions with the FDA and is working on the clinical program requirements for the 510(k) process [29][30] Question: What are the expectations for the upcoming Heart Rhythm Society meeting? - The company is looking forward to presenting both preclinical and clinical data at HRS, highlighting the advantages of nanosecond PFA technology [34][62]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34899 Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 46-5696597 (Sta ...

Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results Exhibit 99.1 Recent Business Highlights HAYWARD, Calif. [Business Wire] – May 7, 2024. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced business updates and financial results for the first quarter ended March 31, 2024. CellFX nsPFA Percutaneous Electrode ●March 2024, received FDA 510(k) clearance for use in th ...

Pulse Biosciences Inc (NASDAQ:PLSE) Q4 2023 Results Conference Call March 28, 2024 4:30 PM ET Company Participants Philip Taylor - IR Kevin Danahy - President & CEO Darrin Uecker - CTO & Director Mitch Levinson - Chief Strategy Officer Mike Koffler - Vice President of Finance Bob Duggan - Executive Chairman Conference Call Participants Brad Bowers - Mizuho Securities Operator Greetings, and welcome to the Pulse Biosciences Fourth Quarter 2023 Earnings Conference Call. At this time, all participants are in a ...

Exhibit 99.1 Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results HAYWARD, Calif. [Business Wire] – March 28, 2024. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2023. Recent Business Highlights CellFX nsPFA Percutaneous Electrode (End-effector of the p ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 46-5696597 (State or ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q3 2023 Earnings Conference Call November 13, 2023 12:00 PM ET Company Participants Philip Taylor - IR Kevin Danahy - President and CEO Darrin Uecker - CTO and Director Mitchell Levinson - Chief Strategy Officer Michael Koffler - VP of Finance Bob Duggan - Chairman Conference Call Participants Operator Greetings, and welcome to the Pulse Biosciences Third Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It ...

(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q For the transition period from to Commission File Number: 001-34899 Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 46-5696597 ...

Pulse Biosciences Inc. (NASDAQ:PLSE) Q2 2023 Results Conference Call August 10, 2023 4:30 PM ET Company Participants Philip Taylor - IR Kevin Danahy - Chief Executive Officer Darrin Uecker - CTO & Director Mitchell Levinson - Chief Strategy Officer Michael Koffler - Director of Finance Bob Duggan - Chariman of the Board of Pulse Biosciences Operator Greetings, and welcome to Pulse Biosciences' Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question ...